Abstract
Despite the increasing availability of novel agents over the past decade, and improved understanding of peripheral T-cell lymphoma (PTCL) ontogeny, outcomes for most PTCL patients remain dismal. Improved understanding of their genetic landscape and the identification of novel therapeutic vulnerabilities has certainly expanded the arsenal of targeted agents, many of which are currently under investigation. Nonetheless, the rarity of these lymphomas continues to frustrate efforts to translate these advances in a manner that is clinically impactful, and this challenge is only compounded by their sheer molecular and genetic heterogeneity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
